Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors (Q37600876)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2009

Language	Label	Description	Also known as
English	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors	scientific article published on September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors (English)

1 reference

Europe PubMed Central

21 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

Sandra Black

14

0 references

author name string

Albert Fournier

1

1 reference

Europe PubMed Central

21 August 2017

Roxana Oprisiu-Fournier

2

1 reference

Europe PubMed Central

21 August 2017

Jean-Marie Serot

3

1 reference

Europe PubMed Central

21 August 2017

Olivier Godefroy

4

1 reference

Europe PubMed Central

21 August 2017

Jean-Michel Achard

5

1 reference

Europe PubMed Central

21 August 2017

Sebastien Faure

6

1 reference

Europe PubMed Central

21 August 2017

Hakim Mazouz

7

1 reference

Europe PubMed Central

21 August 2017

Mohamed Temmar

8

1 reference

Europe PubMed Central

21 August 2017

Adriana Albu

9

1 reference

Europe PubMed Central

21 August 2017

Régis Bordet

10

1 reference

Europe PubMed Central

21 August 2017

Olivier Hanon

11

1 reference

Europe PubMed Central

21 August 2017

François Gueyffier

12

1 reference

Europe PubMed Central

21 August 2017

Jiguang Wang

13

1 reference

Europe PubMed Central

21 August 2017

Naoyuki Sato

15

1 reference

Europe PubMed Central

21 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

21 August 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 reference

Europe PubMed Central

21 August 2017

9

1 reference

Europe PubMed Central

21 August 2017

9

1 reference

Europe PubMed Central

21 August 2017

1413-1431

1 reference

Europe PubMed Central

21 August 2017

The age-dependent relation of blood pressure to cognitive function and dementia

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Fruit and vegetable consumption and stroke: meta-analysis of cohort studies.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Duration of antihypertensive drug use and risk of dementia: A prospective cohort study

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Calcium in ischemic cell death

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

AT(2) but not AT(1) receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Valsartan abolishes most of the memory-improving effects of intracerebroventricular angiotensin II in rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin II type 1 receptor-modulated signaling pathways in neurons.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-Mammalian target of rapamycin pathway

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Telmisartan prevented cognitive decline partly due to PPAR-gamma activation

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Disease-modifying trials in Alzheimer's disease: a European task force consensus

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Recent developments in Alzheimer's disease therapeutics

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Influence of losartan and atenolol on memory function in very elderly hypertensive patients

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin peptides and their pleiotropic actions

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

The angiotensin-converting enzyme gene family: genomics and pharmacology

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Antihypertensive drugs and incidence of dementia: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1586%2FERN.09.89

21 January 2018

Identifiers

10.1586/ERN.09.89

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37600876&oldid=2105029823"